Hello, Fool! | Login | Signup | My Fool
Oct 12, 2008 3:27 PM ET | Feedback | Site Changes | Help
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
View Ticker Page (EXEL)
Results 21 - 30 of 350 : 12345Next »
Recs
cunnin7003 (95.73) Submitted: 9/29/06 5:16 PM : Start Price: $9.00 EXEL Score: -21.62
I've owned this stock for a while, haven't seen any upside yet, but it's coming... someday... Will try to add to my position over time, because in 10 years this could make us all rich.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
TDL5150 (89.98) Submitted: 7/09/08 4:57 AM : Start Price: $5.33 EXEL Score: 5.82
Another MDP recommendation who has taken a beating in recent weeks. That being said - they have a good pipeline and feel it is a great time to buy
majakblue (< 20) Submitted: 3/14/07 12:35 AM : Start Price: $9.01 EXEL Score: 19.43
A product that has not yet reached clinical trials is not yet a product, and it is not even Exelixis' product, it belongs to Genentech. The cost of performing drug discovery is enormous and the $40 million will disappear in short order. The time to...
TMFDiggity (79.48) Submitted: 4/29/06 1:16 AM : Start Price: $10.80 EXEL Score: -30.46
charly's report convinced me
TMFBreakerThiel (31.80) Submitted: 8/18/06 7:52 PM : Start Price: $8.43 EXEL Score: -20.29
A sleeper hit? EXEL is plugging away on that pipeline, and while the BIG catalysts may be a ways off, this is the kind of stock to buy in a down biotech market. Like now. Or last month. Or the month before that. Or.....
Report this Post Replies: 1 | Reply | Permalink
majatester (27.08) Submitted: 7/06/07 4:08 PM : Start Price: $11.95 EXEL Score: -24.23
Non-profitable pharma wannabe with no promising products. Projects are in collaboration with big pharma so guess who will reap the profits in the unlikely event that there are any. But it looks like the market has been taking stupid pills and buyin...
doglo (88.12) Submitted: 11/14/06 1:04 PM : Start Price: $8.56 EXEL Score: -16.89
1. Deep pipeline2. XL880 a. may be most clinically advanced MET inhibitor. b. phase I results showed 14% response rate: significantly higher than 4% industry average. Over 50% of phase I cases reported stable disease. The phase I populat...
JFPauli (< 20) Submitted: 5/18/07 4:29 PM : Start Price: $10.87 EXEL Score: -21.11
This is a well gounded company with many "Big" Brothers on hand to lend a helpful hand. It is not relying on just one possible breakthru but has an excellent stable of candidates.
bluedough (< 20) Submitted: 8/29/06 4:59 PM : Start Price: $8.42 EXEL Score: -20.47
I like EXEL as a speculative pick in biotech because unlike some other ridiculous companies, EXEL HAS THEIR NOSE TO THE GRINDSTONE actually doing something with their cash burn. Even getting a drug to phase II is no small feat, and they have a pipel...
lanoush (22.78) Submitted: 11/02/06 6:12 PM : Start Price: $8.20 EXEL Score: -15.57
This sounds like a relatively safe investment for a biotech with no drugs on the market--it is a takeover target if nothing else, because of its expertise in the lab, and it's deep pipeline, some of which are in early stages.
Terms & Conditions
RSS Headlines
Fool UK